MoleMap NZ远程医疗平台黑色素瘤监测的真实世界结局
结果显示260处(17%)为黑色素瘤,良性:恶性比为5.0:1,每检出1例黑色素瘤需活检6处;有肿瘤厚度数据的137例中92%厚度<0.8 mm,原位黑色素瘤占74%。
要点
- MoleMap NZ远程皮肤镜项目中建议活检的病变黑色素瘤检出率为17%。
- 良性:恶性比为5.0:1,每检出1例黑色素瘤需活检6处。
- 有厚度数据的黑色素瘤中92%<0.8 mm,原位癌占74%。
核心结论
- MoleMap NZ这一社区远程皮肤镜项目有潜力通过远程医疗增加患者获得专家专业知识的途径。
- 需要更多研究来更准确地确定其有效性。
研究设计与样本
- 1571处病变有病理诊断可用。
主要发现
- 1303处(83%)病变为良性,260处(17%)诊断为黑色素瘤。
- 黑色素瘤特异性良性:恶性比为5.0:1,每检出1例黑色素瘤需活检6处(number needed to biopsy=6)。
- 有肿瘤厚度数据的137例黑色素瘤中,92%厚度<0.8 mm(范围从原位至3.1 mm),原位黑色素瘤占74%。
临床怎么用
- MoleMap NZ作为社区远程皮肤镜项目,可用于黑色素瘤早期检测并增加专家服务可及性。
局限性
- 仅分析了建议切除的病变。
- 75%的病例有病理结果可用。
- 53%的诊断黑色素瘤有肿瘤厚度数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: MoleMap NZ is a novel New Zealand-based store-and-forward telemedicine service to detect melanoma. It uses expert review of total body photography and close-up and dermoscopic images of skin lesions that are suspicious for malignancy. OBJECTIVE: The purpose of this study was to assess the effectiveness of MoleMap NZ as a melanoma early detection program. METHODS: We conducted a review of 2108 melanocytic lesions recommended for biopsy/excision by MoleMap NZ dermoscopists between January 2015 and December 2016. RESULTS: Pathologic diagnoses were available for 1571 lesions. Of these, 1303 (83%) lesions were benign and 260 (17%) lesions were diagnosed as melanoma, for a melanoma-specific benign:malignant ratio of 5.0:1. The number needed to biopsy to obtain 1 melanoma was 6. Among melanomas with available tumor thickness data (n = 137), 92% were <0.8 mm (range in situ to 3.1 mm), with in situ melanomas comprising 74%. LIMITATIONS: Only lesions recommended for excision were analyzed. Pathology results were available for 75% of these cases. Tumor thickness data were available for 53% of melanomas diagnosed. CONCLUSIONS: This real-world study of MoleMap NZ, a community-based teledermoscopy program, suggests that it has the potential to increase patients' access to specialist expertise via telemedicine. Additional studies are needed to more accurately define its efficacy.
引用
- Greenwald E, Tan A, Stein JA, et al. Real-world outcomes of melanoma surveillance using the MoleMap NZ telemedicine platform. J Am Acad Dermatol. 2020. PMID: 32114083. doi:10.1016/j.jaad.2020.02.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。